ReviewInternational journal of ophthalmology2026
Subretinal fluid in rhegmatogenous retinal detachment: potential biomarkers and therapeutic targets for proliferative vitreoretinopathy.
Review in International journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhegmatogenous retinal detachment (RRD) is a serious ocular condition marked by the separation of the neuroretina from the retinal pigment epithelium (RPE). The pathogenesis of RRD involves intricate molecular and cellular mechanisms, including inflammation, cell migration, and the activation of proliferative signaling pathways. One of the most challenging complications of RRD is proliferative vitreoretinopathy (PVR), which refers to the proliferation and contraction of fibrocellular membranes on the retinal surface and in the vitreous cavity. PVR is a major cause of surgical failure in RRD, as it can lead to recurrent retinal detachment and severe vision loss. However, the pathogenesis of PVR is not yet fully understood, and the treatment options are quite limited. Recent advances in analytical techniques have offered valuable insights into the molecular alterations present in the subretinal fluid (SRF) of patients with RRD. This review seeks to consolidate the current knowledge regarding the SRF profile in RRD and PVR, emphasizing potential biomarkers and therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.